Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...

Understanding Sickle Cell Anemia and the Need for Early DiagnosisSickle cell anemia is a genetic blood disorder caused by a ...

has been applied to human genome editing and was recently implemented in the first Food and Drug Administration-approved gene-editing drug Casgevy, which treats sickle cell anemia, a blood disorder.

Gallbladder problems are a common complication in individuals with sickle cell disease. These issues often arise due to the breakdown of red blood cells and the subsequent formation of gallstones ...

Prime Medicine, Inc. develops prime editing technologies but lacks proof of concept data despite being in the market for 6 years and IPO for 3 years. The gene editing sector is highly risky, with ...

Copyright 2025 The Associated Press. All Rights Reserved. Chicago Chess Records producer Gene Barge attends a screening of the film “Cadillac Records,” about ...

A GROUNDBREAKING gene-editing treatment for sickle cell disease has been approved for use in the UK by the NHS, offering the potential for a cure. Known as exagamglogene autotemcel (exa-cel), this one ...

Sickle cell anaemia is caused by a mutation in the HBB gene, which provides instructions for making the beta-globin subunit of haemoglobin. The disorder follows an autosomal recessive inheritance ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients This new treatment, known as exagamglogene autotemcel (exa-cel), or simply exa-cel ...

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...